Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Aems
AddedFeb 19, 2024
UpdatedJun 18, 2026
Aems

Aems

Angel

AEMS, founded in 2019, provides atomically engineered materials solutions from Livermore, CA.

HQ
Livermore, CA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

AEMS, founded in 2019 and based in Livermore, California, specializes in atomically engineered materials solutions. The company's core mission is to catalyze new technologies by rapidly functionalizing biomolecule stability matrices using AI. AEMS focuses on addressing the challenges associated with the commercialization of complex biomolecule products, aiming to enhance their quality, reliability, and convenience for healthcare applications.

Notable affiliated individuals and investors have not been specified. However, AEMS has made significant strides in the biotech industry by leveraging advanced AI techniques to improve biomolecule stability. This innovation has the potential to streamline the path for next-generation biomolecule products to reach the market, thereby making a substantial impact on healthcare technology and product development.

Aems - Similar Companies

AMPLY Discovery logo

AMPLY Discovery

amplydiscovery.com

AthemBio logo

AthemBio

athembio.com

Atomic AI logo

Atomic AI

atomic.ai

Ampel Biosolutions logo

Ampel Biosolutions

Aikium logo

Aikium

aikium.com

Atom Bioworks logo

Atom Bioworks

atombioworks.com

Atom AI logo

Atom AI

Aether Bio logo

Aether Bio

aetherbio.com

Automat Solutions logo

Automat Solutions

automatsoln.com

Aibios logo

Aibios

aibios.com

Medium Biosciences logo

Medium Biosciences

medium.bio

Atom logo

Atom

atominc.com

Matterworks logo

Matterworks

matterworksbio.com

Aureka Biotechnologies logo

Aureka Biotechnologies

aurekabio.com

NemaLife logo

NemaLife

nemalifeinc.com

Aems - Quick Facts

Who are Aems' competitors?

Companies similar to Aems include AMPLY Discovery, AthemBio, Atomic AI and Ampel Biosolutions.

When was Aems founded?

Aems was founded in 2019.

Where is Aems' headquarters located?

Aems' headquarters is located in Livermore, CA, US.

When was Aems' last funding round?

Aems' most recent funding round was for $250k (USD) in May 2023.

How much has Aems raised to-date?

As of May 18, 2023, Aems has raised a total of $650k (USD).

How many employees does Aems have?

Aems has 5 employees as of Feb 4, 2024.

Aems - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Materials Solutions
Tags
  • AI
  • Biotech
NAICS
  • 320000Manufacturing
  • 325300Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing
  • 325320Pesticide and Other Agricultural Chemical Manufacturing
  • 325000Chemical Manufacturing
SIC
  • 2870Agricultural Chemicals
  • 2879Pesticides And Agricultural Chemicals, Not Elsewhere Classified
  • 2800Chemicals And Allied Products
Show 2 more industry codes
SIC
  • 2890Miscellaneous Chemical Products
  • 2899Chemicals And Chemical Preparations, Not Elsewhere Classified